Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of F-1614 (I-131 3-iodobenzylguanidine) in pheochromocytoma and paraganglioma
jRCT2080223695Phase 2Completed
- Sponsor
- PDRadiopharma Inc.
- Start
- Oct 2017
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of Iobenguane in pheochromocytoma, Paraganglioma (PGL) and malignant paraganglioma, sponsored by PDRadiopharma Inc. Started Oct 2017; status: completed.
02
Drugs
Iobenguane
03
Conditions
pheochromocytomaParaganglioma (PGL)malignant paraganglioma
Beyond the preview
Go deeper on jRCT2080223695.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223695.